{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-006813","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.113998+00:00","generated_at":"2026-05-16T07:29:38.942814+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cognition Therapeutics completes Type C FDA meeting for zervimesine in DLB; discusses Phase 2b endpoints","bullets":["Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.","Discussed clinically meaningful endpoints for proposed Phase 2b study in mild-to-moderate DLB.","FDA meeting minutes expected later this quarter; no specific outcome disclosed.","Zervimesine is an oral once-daily investigational drug targeting Aβ and α-synuclein toxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-006813","json":"https://secwatch.observer/filing/0001104659-26-006813.json","markdown":"https://secwatch.observer/filing/0001104659-26-006813.md","text":"https://secwatch.observer/filing/0001104659-26-006813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926006813/0001104659-26-006813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926006813/tm264096d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:29:38.942814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}